Science & Enterprise subscription

Follow us on Twitter

  • Nine universities in the U.S. are taking part in a program supporting research and entrepreneurs developing food an… https://t.co/oZ2i6R14UB
    about 3 hours ago
  • New post on Science and Enterprise: Nine Campuses Join Rural Food Research Fund https://t.co/vYlPet30bO #Science #Business
    about 3 hours ago
  • Spark Therapeutics, a developer of gene therapies, is gaining access to a technology that programs DNA sequences li… https://t.co/WGboSsrf7U
    about 24 hours ago
  • New post on Science and Enterprise: Gene Therapy Company Exploring DNA Circuit Technology https://t.co/2YUM4DVZRK #Science #Business
    about 24 hours ago
  • A study with lab mice shows an experimental vaccine with engineered bacteria produces antibodies and protects again… https://t.co/3JtSqD1Sa2
    about 1 day ago

Please share Science & Enterprise

Infographic – Biotech Index Cruising in High Range

NBI, Feb - Aug 2020

Nasdaq Biotechnology Index, 21 Feb. through 21 Aug 2020. Click on image for full-size view (Nasdaq)

22 Aug. 2020. We last looked at the Nasdaq Biotechnology Index in April, and it’s time to check in again with this financial indicator of the index. In April, we saw how the NBI, an index of 206 biotech companies listed on the Nasdaq exchange, began rebounding from the pandemic shock in March, with the likely realization among investors that biotech companies will be at the center of any solutions to Covid-19.

Since April, NBI continued rising until 20 July, when it closed at nearly 4,580, more than 1.5 times its 16 March trough. Since 20 July, the index declined somewhat to yesterday’s close of 4,162. Looking back to May, however, shows that NBI has largely settled in to the 4,000 to 4,500 range, without volatile swings in either direction. The overall Nasdaq Composite Index, an indicator of the technology industry in general, has gained steadily since April, closing yesterday at 11,311, its high point for the year.

As we reported last month, life science and biotech start-ups remained hot venture targets during the first half of 2020, in spite of the pandemic, or maybe because of it. We will see if this investor preference continues, or the mild decline in the NBI since last month is the start of a longer-term trend.

More from Science & Enterprise:

*     *     *

Comments are closed.